Skip to main content
. Author manuscript; available in PMC: 2021 May 25.
Published in final edited form as: Clin Lymphoma Myeloma Leuk. 2018 Aug 29;18(12):788–795.e2. doi: 10.1016/j.clml.2018.08.009

Table 4.

History of Thrombotic Events in 2485 Patients With Evaluable Data

Thrombotic Event N (%)
Any Events Before Enrollmenta 468 (18.8)
 Before diagnosisb 296 (11.9)
  Venous 166 (6.7)
  Arterial 142 (5.7)
 Between diagnosis and enrollmentb 207 (8.3)
  Venous 130 (5.2)
  Arterial 87 (3.5)
More than one thrombotic event 115 (4.6)
Venous Events Before Enrollment 279 (11.2)
 Deep-vein thrombosis 151 (6.1)
 Pulmonary embolism 64 (2.6)
 Superficial venous thrombosis 30 (1.2)
 Portal vein thrombosis 20 (0.8)
 Cerebral vein/sinus thrombosis 17 (0.7)
 Splenic vein thrombosis 9 (0.4)
 Retinal vein thrombosis 7 (0.3)
 Visceral/splanchnic vein thrombosis 1 (<0.1)
 Other 42 (1.7)
Arterial Events Before Enrollment 218 (8.8)
 Cerebrovascular arterial thrombosis 126 (5.1)
 Acute myocardial infarction 44 (1.8)
 Peripheral arterial thrombosis 14 (0.6)
 Splenic infarction 6 (0.2)
 Retinal artery thrombosis 4 (0.2)
 Visceral arterial thrombosis 1 (<0.1)
 Other 38 (1.5)

Patients without known PV diagnosis date were excluded from evaluable patient population.

a

Thrombotic events without event dates were excluded.

b

Patient groups reporting events “before diagnosis” and “between diagnosis and enrollment” are not mutually exclusive.